Proteomics' Direct-to-Consumer Strategy to Commercialize Diagnostic Tests May Face Delays, Euroz Hartleys Says

MT Newswires Live

Jan 23, 2025

Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.

The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.

Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.

Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.

The firm maintained a hold rating and price target of AU$0.72 on Proteomics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505337980"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505337980\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505337980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505337980","market":"sg","top_or_hot":-1,"title":"Proteomics' Direct-to-Consumer Strategy to Commercialize Diagnostic Tests May Face Delays, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.</p><p>Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.</p><p>Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.</p><p>The firm maintained a hold rating and price target of AU$0.72 on Proteomics.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics' Direct-to-Consumer Strategy to Commercialize Diagnostic Tests May Face Delays, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics' Direct-to-Consumer Strategy to Commercialize Diagnostic Tests May Face Delays, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-23 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.</p><p>Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.</p><p>Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.</p><p>The firm maintained a hold rating and price target of AU$0.72 on Proteomics.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7048","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505337980","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505337980","pubTimestamp":1737599961,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Proteomics International Laboratories  may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.The firm maintained a hold rating and price target of AU$0.72 on Proteomics.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7048":"生命科学工具和服务","PIQ.AU":"PROTEOMICS INTERNATIONAL LAB","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，蛋白质组学直接面向消费者的诊断测试商业化战略可能会面临延误","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PIQ.AU":0.9},"content_text":"Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.The firm maintained a hold rating and price target of AU$0.72 on Proteomics.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}